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Abstract
Background: Schizophrenia is considered a language related human specific disease. Previous studies have
reported evidence of positive selection for schizophrenia-associated genes specific to the human lineage. FOXP2
shows two important features as a convincing candidate gene for schizophrenia vulnerability: FOXP2 is the first
gene related to a language disorder, and it has been subject to positive selection in the human lineage.
Methods: Twenty-seven SNPs of FOXP2 were genotyped in a cohort of 293 patients with schizophrenia and 340
controls. We analyzed in particular the association with the poverty of speech and the intensity of auditory
hallucinations. Potential expansion of three trinucleotide repeats of FOXP2 was also screened in a subsample.
Methylation analysis of a CpG island, located in the first exon of the gene, was performed in post-mortem brain
samples, as well as qRT-PCR analysis.
Results: A significant association was found between the SNP rs2253478 and the item Poverty of speech of the
Manchester scale (p = 0.038 after Bonferroni correction). In patients, we detected higher degree of methylation in
the left parahippocampus gyrus than in the right one.
Conclusions: FOXP2 might be involved in the language disorder in patients with schizophrenia. Epigenetic factors
might be also implicated in the developing of this disorder.
Background
It is widely accepted that neutral drift and Darwinian
positive selection have played an important role in the
evolution of human features. During the last few years,
research has been focused on human genome-wide scans
of adaptative evolving loci to search for specific modern
characteristics in this species [1]. Although most of them
are related to fitness, it has been reported that some
genes under positive selection in the human lineage can
also confer vulnerability to some diseases [2-4].
Schizophrenia, which is considered as a disease related
to the origin of Homo sapiens, could be a by-product of
an adaptative process [3,5,6]. Previous reports have indi-
cated a relationship between positively selected genes
and schizophrenia. Crespi eta l .[ 3 ]f o u n ds i g n a l so f
positive selection in 28 of 76 schizophrenia candidate
genes that had been previously reported as positive
results in association studies. Evidence of recent positive
selection in the human lineage has also been found in
haplotypes of MAOB and GABRB2 genes, which also
confer an increased risk to schizophrenia [2,4]. Further-
more, brain areas that are differentially dysregulated in
schizophrenia include the regions most-notably subject
to differential evolutionary change along the human
lineage [7-9]. In addition, it has recently been suggested
that metabolic processes altered in schizophrenia
evolved at a higher rate in the human lineage, when
compared with the chimpanzee [10].
A selective advantage could affect the achievement of
specific human capacities, such as language. In this con-
text, TJ Crow [9,11], postulates that schizophrenia is the
price that Homo sapiens had to pay for the acquisition
of language. Moreover, recent neuroimaging studies
report impairment in brain function relevant to lan-
guage processing in individuals with schizophrenia and
in those who are at a genetic risk for this disease [12].
First evidence for a gene involved in language was
reported in 2001, when the FOXP2 gene was identified by
Lai et al. [13]. Identification of the transcriptional targets
of FOXP2 revealed that this protein could regulate genes
involved in development and function of the brain, genes
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any medium, provided the original work is properly cited.under positive selection in human lineage and genes asso-
ciated to schizophrenia [14]. Apart from the polyglutamine
tracts, the human protein only differs in three amino acids
from its ortholog in mouse, and two of these changes
occurred in the human lineage after separation from the
common ancestor shared with chimpanzees. Both changes
are fixed in human populations, and there is evidence to
support they have been under positive selection [15,16].
Association studies between FOXP2 polymorphisms and
susceptibility to different pathologies of language impair-
ment, such as specific language impairment, dyslexia or
autism have not produced robust results [17], but the
identification of two coding mutations related to verbal
dyspraxia [18]. Nevertheless there are strong evidence of
the importance of the gene in development and some
aspects of language [19] including the fact that CNTNAP2,
a downstream target of FOXP2 has been related also to
language disorders [20,21]. In schizophrenia, preliminary
association studies have delivered controversial results
[22-24]. To the best of our knowledge, no methylation
study of FOXP2 has previously been done.
We hypothesized that FOXP2 could be considered a
candidate gene that may confer vulnerability to schizo-
phrenia or to the language related symptoms of this dis-
order. To test this hypothesis, two different analyses
were carried out: 1) an association study between
FOXP2 polymorphisms and schizophrenia and 2) the
study of the methylation status of the FOXP2 promoter
in different areas of the brain in patients and controls.
Methods
Association study participants
For the association study, 293 patients and 340 healthy
unrelated controls were analyzed. All patients and con-
trols were Caucasians of Spanish descent. Exclusion cri-
teria included organic brain syndromes, mental
retardation, severe drug abuse, or inability to understand
simple questions. Participants with previous psychiatric
treatment were excluded as controls.
There were no significant differences in sex or age for
both groups. All patients met DSM-IV criteria for schi-
zophrenia. The Manchester scale [25], and the psychotic
symptom rating scale (PSYRATS) [26], were used
respectively, to assess the clinical psychotic symptoms,
with particular attention to the Poverty of speech item,
and the intensity of auditory hallucinations. The mean
Manchester score was 8.79 (SD = 5.56) and mean PSY-
RATS score was 16.26 (SD = 23.26). This study was
approved by the local Ethics Committee. All patients
signed the informed consent form.
Post-mortem human brain samples
For methylation and expression analyses, human
brain samples were kindly donated by the London
Neurodegenerative Diseases Brain Bank at the Institute
of Psychiatry. Grey tissue from both hemispheres of the
superior temporal gyrus, parahippocampus gyrus and
cingulate gyrus was obtained. For methylation analyses,
one sample for each region was analyzed for both
patients and controls. For expression analyses, 13 sam-
ples from patients (6 from the right hemisphere and 7
from the left hemisphere) and 12 samples from controls
(9 from the right and 3 from the left hemisphere) were
analyzed.
Association study
Genomic DNA was extracted from peripheral blood leu-
kocytes by the Puregene kit (Gentra Systems, MN,
USA).
A total of 27 polymorphisms were analyzed, 10 of
them by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) and 17 by an iPLEX
genotyping assay (Sequenom, CA, USA). Details of the
primer sequences, PCR conditions and restriction
enzymes are described in Additional files 1 and 2.
Three regions were screened for potential trinucleo-
tide expansions: two polyQ tracts of 40 and 10 residues,
located respectively in exons 5 and 6 of FOXP2,a n da
CGG-rich region in intron s1 close to the transcription
start site. Primers flanking the three regions were
designed (see Additional file 1). One primer in each pair
was 5’-labeled with 6-FAM or HEX fluorophores. Fluor-
escent amplicons were electrophoresed with internal
lane size standards in an ABI PRISM® 3700 DNA Analy-
zer (Applied Biosystems Inc.) and length of fragments
was analyzed with the GeneScan-v3.7 (Applied Biosys-
tems, Inc.).
Statistical and genetic analyses were performed using
Haploview v4.1, UNPHASED 3.10, and SSPS v13 soft-
ware. Bonferroni correction was used for multiple tests.
For the haplotype association study, four marker sliding-
windows were used, with the exception of a five marker
haplotype, for which association had been detected in a
previous study [24].
Methylation analysis
DNA from brain samples was extracted using a
Nucleon® Genomic DNA Extraction Kit (Tepnel Life
Sciences). DNA from leukocyte samples was extracted
using the Puregene kit (Gentra Systems).
DNA was fragmented with EcoRI (New England Bio-
labs) prior to overnight digestion with Proteinase K
(Sigma Aldrich). DNA was cleaned, purified and con-
centrated using a Qiaex II kit (Qiagen). The processed
DNA samples were treated with either the CpGenome™
DNA Modification Kit (Chemicon® International) or the
EpiTect Bisulfite Kit (Qiagen) in accordance with the
supplier’s guidelines.
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phite-converted DNA (see Additional file 1). PCR frag-
ments were cloned into the PCR 2.1 vector using the
TOPO cloning kit (Invitrogen), or pGEM-T® vector
using the pGEM-T® Easy Vector System (Promega), and
sequenced with T7 and SP6 universal primers.
Expression analysis
Total RNA was extracted with the RNeasy Lipid Tissue
Mini Kit (Qiagen). Reverse transcription of 1 μg of RNA
was performed using SuperScriptTM III Reverse Tran-
scriptase (Invitrogen) and random primer hexanucleo-
tides (Promega).
Quantitative RT-PCR was performed in triplicate for
each sample on an iCycler iQ Real Time PCR System
(Qiagen) with Power SYBR® Green PCR Master Mix
(Applied Biosystems) using a standard protocol. Specific
cDNA primers for FOXP2 and RPII,u s e da sac o n t r o l
gene, were designed. Sequences and PCR conditions are
shown in Additional file 1. The comparative CT method
(ΔΔCT) was used to measure the relative gene
expression.
Results
Association study
Twenty-four intronic SNPs and three SNPs within the 5’
untranslated region of FOXP2 were selected for this
study. The SNPs rs13308496 and rs10254225 were
monomorphic in our sample. In Figure 1, we show the
location of the selected SNPs that were polymorphic in
our sample. All of the SNPs were at Hardy-Weinberg
equilibrium in both patients and controls, except
rs717233, which deviated from HWE in controls (see
Additional file 3) and was removed in further analyses.
A l l e l i ca n dg e n o t y p i cf r e q u e n c i e so ft h et w e n t y - f o u r
SNPs in both patients and controls are shown in Addi-
tional file 4. Minor allele frequencies for the SNPs ran-
ged between 0.02 and 0.49.
First, we conducted the single SNP association analy-
sis. When all patients were included, we observed a sig-
nificant association for the SNP rs10447760 at allelic
frequencies, although this association did not remain
after applying the conservative Bonferroni correction.
When comparing patients with auditory hallucinations
versus controls (see Additional file 5), significant asso-
ciations were found for SNP rs2396753 and SNP
rs17137124. However, after Bonferroni correction, the
significant associations were also lost.
Finally, when patients with auditory hallucinations
were compared with patients without hallucinations
(see Additional file 6), a significant association was
found for SNP rs2253478 and SNP rs1456031 in geno-
typic frequencies and for SNP rs2396753 in both, gen-
otypic and allelic frequencies. However, once again,
after Bonferroni correction, the significance disap-
peared in all cases.
Next, we carried out the haplotypic association analy-
sis. Tests of four marker haplotypes did not provide evi-
dence of significant associations with schizophrenia or
auditory hallucinations. However, when we took into
account the five marker haplotype which was found to
be significant in a previous study [24], positive results
were detected for the same combination of alleles:
rs7803667T/rs10447760C/rs923875A/rs2396722C/
rs2396753A (c2 = 6.479; p = 0.0109). Interestingly, this
combination of alleles was found more frequent in
controls than in schizophrenic patients with auditory
hallucinations.
Linear regression was performed to evaluate the asso-
ciation between the SNPs and the items of the PSY-
RATS and Manchester scales. After Bonferroni
correction was applied, only association between SNP
rs2253478 and the Poverty of speech was maintained
(p corrected = 0.038).
With regard to the analyses of potential expansions of
trinucleotide tracts of FOXP2, no variation was found in
a n yo ft h e s er e g i o n si no u rs a m p l e .O n l yas i n g l ed e l e -
tion of three trinucleotides at the CGG-rich region in
intron s1 was identified in heterozygosis in a patient
with schizophrenia.
Methylation analyses
FOXP2 has four independent transcriptional start sites
that would be termed exon s1, exon 1, exon 1b and
exon 2 using the conventional designations of its initia-
tion exon. In this work, we have focused on the study of
region including exon s1, which is considered a basal
transcription start site. Figure 2 shows a diagram of the
region studied.
For the region named CG1 bisulphite region, no dif-
ferences were found between patients and controls or
between brain areas. This region, located upstream
of exon s1 was characterized by a general absence of
methylation in all the samples analyzed. In the case of
CG2 bisulphite region, located downstream of exon s1,
a higher degree of methylation was found with respect
to CG1. In addition, subtle differences were found for
the parahippocampus gyrus. Within this brain area, the
methylation degree is higher than in the other areas
analyzed in both patients and controls. When right and
left parahippocampus gyrus regions were compared, dif-
ferences in the degree of methylation between patients
and controls were identified (Figure 3). In patients, the
degree of methylation is higher in the left hemisphere of
the parahippocampus gyrus than in the right one,
whereas in controls, methylation is concentrated more
in the right hemisphere of the parahippocampus gyrus
region. Interestingly, most of the clones that were
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Page 3 of 8Figure 1 Structure of FOXP2 gene. Hash marks indicate introns longer than 50 kb. Arrows indicate positions of all single nucleotide
polymorphisms (SNPs) analyzed in this study: arrows indicate SNPs polymorphic in our sample. Distances of SNPs to +1 site (5’ end of s1 exon)
are shown in brackets.
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Page 4 of 8Figure 2 CpG dinucleotides in the context of the CpG island located in transcription start site. The thin black line corresponds to the
sequence of DNA. Below this, a single black bar corresponds to the predicted CpG island location. Distances in base pairs to +1 site are
included, as well as an arrow indicating the start site of exon s1. Primers for both regions analyzed, CG1 and CG2 are indicated with arrows.
Figure 3 Bisulfite results for parahippocampus gyrus. Methylation data are represented as filled circles (methylated CpG) and empty circles
(unmethylated CpG) for each bacterial clone obtained. Each row of circles represents the methylation pattern based on the sequence of one
cloned PCR product.
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A high degree of methylation in the CG2 region was
also found in leukocyte samples of controls. In this case,
the observed methylation pattern is different from the
one obtained from brain samples of controls.
Generally, a high degree of methylation on the promo-
ter region of a gene is correlated with lower RNA
expression levels. Therefore, differences in the degree of
methylation could result in differential expression of the
gene. When comparing the relative expression level of
FOXP2 in parahippocampus gyrus between patients and
controls, higher levels of FOXP2 mRNA expression were
obtained in the right hemisphere in patients (Figure 4).
This correlates inversely with methylation results, which
show a greater degree of methylation in controls than in
patients. However, when expression levels from the left
and right hemispheres were compared in patients, no
correlation was found, since expression is higher in left
p a r a h i p p o c a m p u st h a ni nr i g h t ,a sw e l la st h el e v e lo f
methylation. These findings do not support the idea that
a high degree of methylation leads to decreased expres-
sion of the gene.
Discussion
In this study we investigated the role of FOXP2,ap o s i -
tively selected gene, in schizophrenia vulnerability. A
SNP association study, with particular attention to lan-
guage related symptoms as auditory hallucinations and
poverty of speech, and a study of DNA methylation and
expression of this gene were carried out.
The most important finding of this study is the sig-
nificant association showed between the rs2253478
SNP and the item of Poverty of speech of the Manche-
ster scale (p = 0.038 after Bonferroni correction). This
polymorphism is located in intron s3, not close to any
of the promoter regions. There is no information that
it could be an enhancer of splicing element. Its poten-
tial functionality has not been yet investigated, and
then it is difficult to determine the biological signifi-
cance of this association. Alternatively it could be in
linkage disequilibrium with another polymorphism
being the causative factor. In any case, our results
relate the FOXP2 gene to one of the characteristic
symptoms of schizophrenia, deficits in the language
domain [27-29].
On the other hand, the haplotypic analysis confirmed
our previous results that the rs7803667T/rs10447760C/
rs923875A/rs2396722C/rs2396753A haplotype could be a
protective one with respect to auditory hallucinations [24].
It has been suggested that specific language-related
circuits are affected in patients with schizophrenia [12].
Therefore, it is reasonable to look for risk alleles to schi-
zophrenia vulnerability in FOXP2, a gene for which an
implication in the development of language is well
accepted [13,30]. Nevertheless, schizophrenia is a biolo-
gical entity not well defined, indicative of a phenotype
too much complex for genetic analysis, which partially
explains the difficulty to find the causative genetic fac-
tors. At this point, the study of language variables in
order to find risk alleles in schizophrenia becomes a
good alternative with respect to endophenotype
approaches. Our results support this hypothesis, since
significant results were found when we related language
impairment in schizophrenic patients to FOXP2
polymorphisms.
In this work, we also analyzed whether the polyQ
stretches at exons 5 and 6 of FOXP2 are polymorphic
and if so, determine its potential association with schi-
zophrenia vulnerability. Expansions in the number of
trinucleotides repeats are frequently associated with
neurodegenerative diseases [31]. However, no variation
in the number of glutamines was found in our sample.
This high stability is concordant with previous studies
in controls, individuals with progressive movement dis-
orders, and schizophrenic patients [32,33]. The role of
the polyQ tracts in the FOXP2 gene is unknown. In fact,
most of the members of the FOX family lack this
domain. Nevertheless, the high invariability of these
sequences suggests that they could be under functional
constraints.
In addition to schizophrenia vulnerability due to varia-
tions in the DNA sequence, epigenetic factors regulating
gene expression have also been suggested as a potential
etiological mechanism in psychosis [34,35]. Epigenetic
regulation has been increasingly associated with psychia-
tric disorders, with examples in depression and addic-
tion [36,37].
Figure 4 Levels of FOXP2 expression in parahippocampus
gyrus brain area.
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r e g i o n ,w ef o u n dah i g h e rd e g r e eo fm e t h y l a t i o ni nt h e
left hemisphere of the parahippocampus gyrus region in
patients than in controls. From these results, we would
have expected lower gene expression of FOXP2 due to
repression by methylation. However, no differences were
found in FOXP2 expression between controls and
patients. This discrepancy could be explained by the fact
that only a stretch of the CpG island, located in exon
s1, was analyzed for methylation. The promoter region
of the FOXP2 gene has not been well defined, and regu-
lation of the gene is more complex than was initially
thought (non published personal data, [38]). The finding
that expression data show a trend of more expression in
patients than in controls would indicate that a decrease
of neural processes controlled by the protein FOXP2, a
repressor of transcription, is produced in patients. Hip-
pocampal and parahippocampal volume reduction is one
of the most consistent findings in schizophrenia [39].
Moreover, in a meta-analysis of brain volumes in rela-
tives of patients with schizophrenia, hippocampal reduc-
tion was the largest difference between relatives and
healthy controls [40]. These findings suggest hippocam-
pal volume as a potential end of phenotype for genetic
studies in schizophrenia.
Our study has some limitations. First, the language
skills evaluated in this work include only two items of
the Manchester scale. Since the strongest result is
related to one of these items, we would recommend a
systematic exploration of language variables in schizo-
phrenic patients. Therefore, it would be valuable to
explore different aspects of language in future studies.
Second, we have used a small sample in the methylation
and expression analyses so further studies with a larger
sample would be necessary in order to confirm our pre-
liminary results. Finally, other variables which could
affect methylation, such as medication or age, should be
considered. In spite of these limitations, this study sug-
gests the use of the language related disorder as alterna-
tive phenotypes in schizophrenia for genetic studies. On
the other hand, although the results are not conclusive,
this is the first epigenetic study of FOXP2 in schizophre-
nia, opening a new way in which this gene could be
related to this disorder.
Conclusions
Our results do not support the involvement of FOXP2
in the vulnerability to schizophrenia as a global syn-
drome. Nevertheless, this gene might be implicated in
schizophrenia through its role in language impairment.
Epigenetic mechanisms affecting the expression of
FOXP2 might contribute to the development of schizo-
phrenia and related neurodevelopmental disorders.
Additional material
Additional file 1: Sequences of primers used in the association
study, analysis of potential expansions of trinucleotides,
methylation analyses and quantitative PCR. For SNP rs6961558, one
of the primers was modified in order to create a restriction enzyme
target depending on the allele in the sequence. Modified nucleotide is
shown in grey.
Additional file 2: RFLPs conditions.
Additional file 3: Results for Hardy-Weinberg equilibrium test in
patients and controls.
Additional file 4: Genotype and allele frequencies of the analyzed
SNPs in patients and controls.
a tests in which expected values for
more than one class are lower than 5. * it corresponds to corrected
p value (Bonferroni correction).
Additional file 5: Genotype and allele frequencies of the analyzed
SNPs in patients with auditory hallucinations (AH) and controls.
a
tests in which expected values for more than one class are lower than 5.
b tests in which due to lack of some classes, it was used a table 2 × 2
instead a 3 × 2. * it corresponds to corrected p value (Bonferroni
correction).
Additional file 6: Genotype and allele frequencies of the analyzed
SNPs in patients with auditory hallucinations (AH) and patients
without AH.
a tests in which expected values for more than one class
are lower than 5.
b tests in which expected values for one class are lower
than 2.
c tests in which due to lack of some classes, it was used a table
2 × 2 instead a 3 × 2. * it corresponds to corrected p value (Bonferroni
correction).
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